News Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:23 14/01/2026 pm IST			After hours 02:29:52 am
6.406 ^EUR	-2.23%		6.393	-0.20%

13/01	Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec	RE
08/01	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies	MT

13/01	Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec	RE
12/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
08/01	Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies	MT
08/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
08/01	Evotec Remains in Demand on Tradegate – Funding Secured for Subsidiary	DP
08/01	Just – Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access	EQ
07/01	Evotec Continues Upward Trend Following Amgen's Acquisition of Dark Blue	DP
07/01	EVOTEC : RBC reiterates its Buy rating	ZD
06/01	Evotec : Declaration of Compliance with the German Corporate Governance Code for the year 2025 (December 2025) 51.097 KB	PU
06/01	Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million	DJ
06/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
06/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
05/01	Amgen Inc. acquired Dark Blue Therapeutics Ltd from Oxford Science Enterprises, Bristol-Myers Squibb Company and Evotec SE in a transaction valued at $840 million.	CI
02/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
02/01	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
02/01	Evotec SE Announces Executive Changes	CI
01/01	Evotec : Current Company Presentation 999.321 KB (2026 01 EVT Company Presentation)	PU
01/01	Evotec appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations	EQ
29/12	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
22/12	Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
17/12	Evotec SE Equity Buyback announced on August 6, 2024, has expired.	CI
09/12	Evotec SE: Prof. Dr. Iris Löw-Friedrich, buy	EQ
09/12	Sources: Novo Nordisk Group Holding reduces stake in Evotec	DP
09/12	Evotec secondary ABB priced at EUR 5.10 per share, bookrunner says	RE
09/12	Bookrunner says Evotec secondary ABB books are closed	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Filters